Rhythm Pharmaceuticals Presents Patient-reported

Rhythm presents first-ever hypothalamic obesity patient-reported experiences with hyperphagia and positive changes in energy and sleep at ENDO2024 ...

Related Keywords

United Kingdom ,United States ,Boston ,Massachusetts ,Michigan ,David Connolly ,Caroline Huber ,David Meeker ,Adam Daley ,Christian Roth ,Danica Grujic ,European Union ,Energy In Acquired Hypothalamic Obesity ,Seattle Children Research Institute ,Corporate Communications ,Berry Company Public Relations ,Rhythm Pharmaceuticals ,Nasdaq ,Clinical Development ,Rhythm Pharmaceuticals Inc ,Division Of Metabolism ,Division Of Endocrinology ,Department Of Pediatrics ,University Of Washington ,Medicines Healthcare Products Regulatory Agency ,Exchange Commission ,Translational Research Development ,Endocrine Society Annual Meeting Expo ,European Commission ,University Of Michigan ,Drug Administration ,Endocrine Society Annual Meeting ,Chief Executive Officer ,Seattle Children ,Research Institute ,Caregiver Reported Experiences ,Acquired Hypothalamic Obesity Before ,During Setmelanotide Therapy ,Senior Director ,Non Clinical Development ,Translational Research ,Associate Professor ,Real World Evidence ,Chronic Weight Management ,Healthcare Products Regulatory Agency ,Pre Existing Nevi ,Sexual Arousal ,Suicidal Ideation ,Serious Adverse Reactions Due ,Benzyl Alcohol Preservative ,Low Birth Weight Infants ,Yellow Card Scheme ,Product Characteristics ,Prescribing Information ,Important Safety ,Private Securities Litigation Reform Act ,Quarterly Report ,Investor Relations ,